Aclaris Therapeutics

NAS:ACRS

Pharmaceuticals: Other

Market Cap

$263.71mm

SMALL cap

Share Price ↑

$6.42 (0.39%)

YTD Return ↓

-16.5796%

since start of 2019

P/E Ratio

—

ACRS chart by TradingView

Source: FactSet financial data and analytics.

Corporate Values

Carbon Footprint
Pollution Prevention
Water Conservation
Data Privacy
Consumer Health
Employee Satisfaction
Workplace Safety
Corp Gov
Ethical Practices
Conflict Materials
Forced Labor
Gender Diversity

Legend

About

Pharmaceuticals: Other Founded 2012

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in identifying, developing and commercializing novel drugs to address unmet needs in dermatology. It also pursues the development of topical agents for the treatment and prevention of a number of medical and cosmetic indications. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.

website

Source: FactSet Research Systems

Headquarters

101 Lindenwood Drive

Suite 400

Malvern, PA 19355

1.484.324.7933

Executives

Name	Title	Gender
Neal S. Walker, PhD, MBA	President, Chief Executive Officer & Director	Male
Michael Stephen Tung, MD, MBA	Vice President-Investor Relations	Male
Stephen A. Tullman	Chairman	Male
Kamil Ali-Jackson	Chief Legal Officer	Female
Frank Ruffo, CPA	Chief Financial Officer	Male
Christopher V. Powala	Chief Operating Officer	Male
Stuart D. Shanler, MD	Chief Scientific Officer	Male

Mindful Investing Summary

Legend

Carbon Footprint — N/A

Aclaris Therapeutics among its competitors for its carbon footprint. A company’s performance in this category is based on its success in implementing energy efficiency measures. Investments in energy efficient technology, green building and sourcing of renewable energy can all lead to cost savings and reduce the company’s contribution to climate change.
Pollution Prevention — N/A

Aclaris Therapeutics on this issue. Companies are evaluated on pollution prevention by the levels of waste (including hazardous waste) they produce and release into the environment, and can be affected by whether they develop products that can reduce exposure to pollution.
Water Conservation — N/A

Aclaris Therapeutics among its peers in this category. A company’s score in this category depends on its measures to minimize water usage and impacts on stressed or drought-prone water resources.
Data & Privacy Protection — N/A

Aclaris Therapeutics among its peers and competitors for data privacy and protection. Companies today digitally manage vast amounts of personal information about their clients. A company’s score on this issue is based on the systems, products and procedures it has in place to minimize the risk for data and privacy breaches.
Consumer Health, Wellness & Safety — N/A

Aclaris Therapeutics compared to its peers and competitors Companies in this category manage its product and safety risks.
Employee Ownership, Satisfaction, Benefits & Pay — N/A

Aclaris Therapeutics among its peers for employee satisfaction and pay. A company’s score on this issue depends on its frequency and likelihood of labor disputes as well as its practices to keep and retain talent - such as compensation, family leave, employee health care and other benefits. Employers that are rated as good to work for consistently produce higher stock returns than their peers.
Workplace Health and Safety — N/A

Aclaris Therapeutics among its competitors on this issue. A company’s workplace health and safety is evaluated not only by the number of accidents and injuries in the workplace, but also by their safety policies, training procedures, and their investment in equipment that can reduce accidents.
Integrity of Corporate Governance — N/A

Aclaris Therapeutics among its competitors on corporate governance. This score is determined by the company’s accounting practices, executive pay, board organization and ownership structure.
Ethical Practices — N/A

Aclaris Therapeutics compared to its peers and competitors. A company’s rating on this issue is based on its history of controversies related to unethical corporate behavior, such as false claims about their products, price fixing, executive misconduct, insider trading or fraudulent practices.
Usage of Conflict Materials — N/A

Aclaris Therapeutics among its competitors in this category. Certain products use raw materials that are commonly sourced from militias or other organizations that promote or engage in conflict in their region. To perform well in this category companies must provide adequate assurances that any of these metals used in their production are in fact from conflict-free sources.
Forced Labor — N/A

Aclaris Therapeutics compared to its competitors on forced labor. A company’s score on this issue depends on its use of forced labor and on its work conditions for outsourced labor.
Diversity of Corporate Leadership 2 N/A

Aclaris Therapeutics performs poorly based on its peers as well as companies in similar geographic regions. Companies are assessed on factors such as board diversity and senior management diversity. Companies performing well on this issue typically are more profitable than its peers, while companies with very poor scores typically have greater stock price volatility and lower returns on capital.

Aclaris Therapeutics - Competitors and Related Companies

How Aclaris Therapeutics stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.